scholarly journals Effect of Anti-Programmed Cell Death Protein-1 Antibody Combined with Paclitaxel on Cervical Cancer via Phosphoinositide 3-Kinase/Protein Kinase B Pathway in Rats

2021 ◽  
Vol 83 (4) ◽  
Author(s):  
Chong Shi ◽  
G. Zhang ◽  
Liyan Peng ◽  
K. Zhang
Keyword(s):  
Cervical Cancer ◽  
Cell Death ◽  
Protein Kinase ◽  
Programmed Cell Death ◽  
Protein Kinase B ◽  
Phosphoinositide 3 Kinase ◽  
Cell Death Protein

Die Systemtherapie des fortgeschrittenen Melanoms im Jahr 2016

2017 ◽  
Vol 5 (3) ◽  
pp. 126-133
Author(s):  
Markus Vincent Heppt ◽  
Cecilia Dietrich ◽  
Saskia Graf ◽  
Thomas Ruzicka ◽  
Julia Tietze ◽  
...  
Keyword(s):  
Cell Death ◽  
Protein Kinase ◽  
Programmed Cell Death ◽  
T Lymphocyte ◽  
Checkpoint Blockade ◽  
Mitogen Activated Protein Kinase ◽  
Mitogen Activated Protein ◽  
Cell Death Protein

Das Melanom ist eine häufige Form von Hautkrebs mit hoher Tendenz zur Metastasenbildung. Tyrosinkinase-Inhibitoren, die zielgerichtet in den MAPK (mitogen-activated protein kinase)-Signaltransduktionsweg eingreifen, sowie die Immun-Checkpoint-Blockade haben in jüngster Zeit die Behandlung des nicht-resezierbaren und des metastasierten Melanoms revolutioniert. Doch erworbene Resistenzen und primäres Nichtansprechen auf diese Therapien machen neuartige Behandlungsstrategien und Kombinationsansätze erforderlich. Das Ziel dieser Übersichtsarbeit ist es, einen kurzen und aktuellen Überblick über das klinische Management des Melanoms und die gegenwärtige Studiensituation zu geben. Die Arbeit enthält Zusammenfassungen der relevantesten Studien zu BRAF- und MEK-Inhibitoren sowie zu Antikörpern gegen CTLA-4 (T-lymphocyte-associated protein 4) und PD-1 (programmed cell death protein 1). Während die meisten Wirkstoffe schon in Monotherapie eine gute antitumorale Wirksamkeit zeigen, sind durch Kombinationstherapien mit zugelassenen und in der Entwicklung befindlichen Wirkstoffen weitere Verbesserungen erzielt worden. Wir besprechen hier laufende Studien und evaluieren Ansätze, die künftig eine noch höhere Wirksamkeit bei geringerer Toxizität gewährleisten könnten. Übersetzung aus Oncol Res Treat 2016;39:635-642 (DOI:10.1159/000448904)

scholarly journals Molecular Biological Tools in Cancer Diagnostics with a Case Study

2020 ◽  
Vol 8 (09) ◽  
pp. 77-84
Author(s):  
Fawzaan Hashmi
Keyword(s):  
Cell Proliferation ◽  
Cell Death ◽  
Protein Kinase ◽  
Protein Kinase B ◽  
Cancer Diagnostics ◽  
Protein Classification ◽  
Diagnostic Strategy ◽  
Mechanistic Target Of Rapamycin ◽  
Phosphoinositide 3 Kinase

Projects of cancer diagnostics are significantly variegated. Manifestly, however, understanding molecular biology can accomplish a great deal in the midst of any diagnostic strategy. This report will seek to indicate some of the key bases of molecular biomedical study, including the foundations of cell growth, cell death, and genetics, together with specific instances of protein classification, as they pertain to cancer. Methodologies of cancer analysis and treatment that cover similar molecular ground will then be elucidated. This will all serve to anchor an examination of the MET/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway, linked to problematic cell proliferation in oncogenesis.

Lupeol Inhibits Proliferation and Promotes Apoptosis of Ovarian Cancer Cells by Inactivating Phosphoinositide-3-Kinase/Protein Kinase B/ Mammalian Target of Rapamycin Pathway

2020 ◽  
Vol 19 (2) ◽  
pp. 206-210
Author(s):  
Feng Chen ◽  
Bei Zhang
Keyword(s):  
Cell Cycle ◽  
Ovarian Cancer ◽  
Protein Kinase ◽  
Cell Viability ◽  
Cancer Cells ◽  
Protein Kinase B ◽  
Mammalian Target Of Rapamycin ◽  
Target Of Rapamycin ◽  
Ovarian Cancer Cells ◽  
Phosphoinositide 3 Kinase

Lupeol exhibits multiple pharmacological activities including, anticancerous, anti-inflammatory, and antioxidant. The aim of this study was to explore the anticancerous activity of lupeol on ovarian cancer cells and examine its mechanism of action. To this end, increasing concentrations of lupeol on cell viability, cell cycle, and apoptosis in Caov-3 cells were evaluated. Lupeol inhibited cell viability, induced G1 phase arrest in cell cycle, increased cell apoptosis, and inhibited the ratio of phospho-Akt/protein kinase B and phospho-mammalian target of rapamycin/mammalian target of rapamycin. In conclusion, these data suggest that lupeol may play a therapeutic role in ovarian cancer.

The role of programmed cell death ligand-1/ programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy

2020 ◽  
Vol 27 ◽  
Author(s):  
Lifang Zhang ◽  
Yu Zhao ◽  
Quanmei Tu ◽  
Xiangyang Xue ◽  
Xueqiong Zhu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Immune Escape ◽  
Hypoxia Inducible Factor ◽  
Hpv Infection ◽  
Advanced Cervical Cancer ◽  
Cervical Carcinogenesis ◽  
Programmed Cell Death 1

Background: Cervical cancer induced by infection with human papillomavirus (HPV) remains a leading cause of mortality for women worldwide although preventive vaccines and early diagnosis have reduced morbidity and mortality. Advanced cervical cancer can only be treated with either chemotherapy or radiotherapy but outcomes are poor. The median survival for advanced cervical cancer patients is only 16.8 months. Methods: We undertook a structural search of peer-reviewed published studies based on 1). Characteristics of programmed cell death ligand-1/programmed cell death-1(PD-L1/PD-1) expression in cervical cancer and upstream regulatory signals of PD-L1/PD-1 expression, 2). The role of the PD-L1/PD-1 axis in cervical carcinogenesis induced by HPV infection and 3). Whether the PD-L1/PD-1 axis has emerged as a potential target for cervical cancer therapies. Results: One hundred and twenty-six published papers were included in the review, demonstrating that expression of PD-L1/PD-1 is associated with HPV-caused cancer, especially with HPV 16 and 18 which account for approximately 70% of cervical cancer cases. HPV E5/E6/E7 oncogenes activate multiple signaling pathways including PI3K/AKT, MAPK, hypoxia-inducible factor 1α, STAT3/NF-kB and MicroRNAs, which regulate PD-L1/PD-1 axis to promote HPV-induced cervical carcinogenesis. The PD-L1/PD-1 axis plays a crucial role in immune escape of cervical cancer through inhibition of host immune response. creating an "immune-privileged" site for initial viral infection and subsequent adaptive immune resistance, which provides a rationale for therapeutic blockade of this axis in HPV-positive cancers. Currently, Phase I/II clinical trials evaluating the effects of PD-L1/PD-1 targeted therapies are in progress for cervical carcinoma, which provide an important opportunity for the application of anti-PD-L1/anti-PD-1 antibodies in cervical cancer treatment. Conclusion: Recent research developments have led to an entirely new class of drugs using antibodies against the PD-L1/PD-1 thus promoting the body’s immune system to fight the cancer. The expression and roles of the PD-L1/ PD-1 axis in the progression of cervical cancer provide great potential for using PD-L1/PD-1 antibodies as a targeted cancer therapy.

scholarly journals Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide

2006 ◽  
Author(s):  
Anthony Marotta ◽  
Kuljit Parhar ◽  
Rajinder Hundal ◽  
Vincent Duronio ◽  
Baljinder Salh
Keyword(s):  
Cell Death ◽  
Protein Kinase ◽  
Protein Kinase B ◽  
Sulindac Sulfide
Sign in / Sign up

Export Citation Format

Share Document